Laura Joszt, MA

Hepatitis B re-engagement efforts are underreported in lower-resource settings, highlighting gaps in care and the need for greater action.

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

Diet, alcohol, and physical activity offer actionable targets for clinicians managing MASLD, according to Zobair M. Younossi, MD.

A gene tied to poor sarcoma prognosis also rose fastest in pazopanib-sensitive sarcoma cell lines, a new exploratory study suggests.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

A new international platform trial groups rare pediatric sarcoma substudies under 1 protocol to speed drug access and data collection.

The shift toward fibrosis end points and noninvasive biomarkers in MASH trials may ease enrollment, improve assessment, and reduce biopsy use, Zobair M. Younossi, MD, said.

Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses.

A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease and younger adults.

John Kitchens, MD, explores how GLP-1s, novel drug pipelines, and Medicaid access gaps are shaping the future of DME management.

Anti-VEGF has maxed out in diabetic macular edema (DME), but Ang-2 and Wnt pathway approaches could target disease differently, said John Kitchens, MD.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

Dermatologists spend 13 hours weekly on prior authorization as health plans tout an 11% reduction in requests.

Paul Hahn, MD, says access and reimbursement, not innovation, are retina care’s biggest barriers and outlines where the field is headed next.

Designated teams, standardized SOPs, and scalable workflows are essential before a community practice's first bispecific dose.

In trials, the first oral PCSK9 inhibitor cut LDL cholesterol by up to 60%, which matched the efficacy of injectable PCSK9 therapies.

Health system executives say Medicaid cuts, payer disputes, and misaligned incentives are driving the affordability crisis in 2026.

New topicals, orals, and biologics are expanding chronic hand eczema treatment, but phenotype-specific data gaps remain.

Paul Hahn, MD, on what separates practice-changing retina therapies from niche ones, plus gene therapy and home-monitoring hurdles.

Carl Regillo, MD, on missed wet AMD injections, treatment switching, and how gene therapy could ease chronic burden.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

Carl Regillo, MD, explains why wet AMD anti‑VEGF results lag in real life and how newer agents extend dosing, yet the burden persists.

FIB4 testing can catch liver disease early, but Naim Alkhouri, MD, and Chika Anekwe, MD, say it remains underused in obesity and primary care.

Insurance and socioeconomic factors delay optimal anti-VEGF care for diabetic macular edema, worsening vision disparities.

Hidden costs, travel, and dilation can derail DME care, but clinicians can build adherence plans that keep working adults on vision-saving therapy.

Community oncology practices are building bispecific programs in diverse configurations to retain patients and scale safely.

Zobair Younossi, MD, explains why fibrosis, not steatohepatitis resolution, best predicts MASH outcomes in trials.

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

Commercial health care costs are projected to grow 9% in 2027, driven by AI billing tools, pharmacy spend, and provider consolidation, per a PwC report.